Tacken Paul J, de Vries I Jolanda M, Torensma Ruurd, Figdor Carl G
Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Tumour Immunology, Postbox 9101, Nijmegen, 6500HB, Netherlands.
Nat Rev Immunol. 2007 Oct;7(10):790-802. doi: 10.1038/nri2173.
The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses has stimulated research on harnessing DCs to create more effective vaccines. Early clinical trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell responses have provided proof of principle. Here, we discuss how direct targeting of antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo culturing, and facilitate large-scale application of DC-based vaccination therapies.
树突状细胞（DCs）可协调先天性和适应性免疫反应，这一认识推动了利用DCs研发更有效疫苗的研究。早期临床试验探索了体外加载抗原的自体DCs以诱导T细胞反应，为这一原理提供了证据。在此，我们讨论了在体内将抗原直接靶向DC表面受体如何可能取代费力且昂贵的体外培养，并促进基于DC的疫苗接种疗法的大规模应用。
